Clinical-stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) reported its third quarter financial results and operational highlights for the period ended September 30, 2022.

Numbers show total cash was over $2.6 million (CA$3.5 million), compared to $3.47 million (CA$4.6 million) on the period ended December 31, 2021.

R&D expenses were $133.505 (CA$176,946) and $386.948 (CA$512,854) for the three and the nine months ended September 30, 2022, respectively, as compared to $133.096 (CA$176,403) and $328.104 (CA$434,863) for the same periods ended September 30, 2021. 

Net and …

Full story available on Benzinga.com